Pharmaceuticals
Zydus Lifesciences acquires Assertio in ₹1,570 crore US expansion push
By Cygnus | 14 May 2026
Zydus Lifesciences will acquire US-based Assertio Holdings for about $166 million, expanding its oncology and specialty pharmaceutical business in the United States.
Novartis expands India’s role in global drug development and R&D
By Axel Miller | 11 May 2026
Novartis is expanding India’s role in pharmaceutical R&D, clinical research and innovative medicines following its strategic restructuring in the country.
Novo Nordisk explores AI partnerships to accelerate drug discovery and manufacturing efficiency
By Cygnus | 14 Apr 2026
Novo Nordisk and global pharma firms are adopting AI to improve drug discovery, manufacturing efficiency, and clinical research in obesity treatments.
Indian drugmakers prepare lower-cost versions of Ozempic-like drugs as competition intensifies
By Axel Miller | 23 Mar 2026
Indian pharma companies prepare affordable semaglutide alternatives as demand for diabetes and weight-loss treatments grows in India.
India sees early competition in semaglutide as drugmakers prepare lower-cost versions
By Axel Miller | 20 Mar 2026
Indian pharmaceutical companies are exploring lower-cost semaglutide options, aiming to expand access to diabetes and obesity treatments.
Zydus and Lupin partner to co-market semaglutide injections in India
By Cygnus | 17 Mar 2026
Zydus and Lupin sign a licensing deal to co-market semaglutide injections in India, introducing a reusable pen device for diabetes and weight-management therapy.
CDSCO warns pharma firms over ‘surrogate’ ads for obesity drugs
By Axel Miller | 12 Mar 2026
CDSCO warns pharma firms against indirect promotion of GLP-1 weight-loss drugs ahead of generic launches.
Sun Pharma Gets DCGI Nod for Generic Wegovy, Set for March Launch as Semaglutide Patent Nears Expiry
By Axel Miller | 23 Jan 2026
Sun Pharma has received DCGI approval for generic semaglutide for weight management and will launch Noveltreat after the semaglutide patent expires in March 2026.
Sun Pharma Weighs $10 Billion Takeover of Organon to Expand US Footprint
By Cygnus | 19 Jan 2026
Sun Pharma is evaluating a ~$10B acquisition of Organon to expand its U.S. footprint in women's health and biosimilars, according to reports.
Johnson & Johnson Cuts Drug Prices to Secure Tariff Exemptions in Trump Deal
By Cygnus | 09 Jan 2026
Johnson & Johnson agrees to cut U.S. drug prices in exchange for tariff relief from the Trump administration and plans new factories in North Carolina and Pennsylvania.
